Two generic pharmaceutical companies, Generic Partners and Apotex, have filed cross-claims alleging that Neurim Pharmaceuticals’ patent for its insomnia drug Circadin is invalid and should be revoked.
IP Australia has ordered biotech firm MacroGenics to amend its patent for a type of polypeptide used in treatments for cancer, autoimmune disorders and other diseases after a successful opposition from the chairman of intellectual property boutique Wrays.
McDonald’s is seeking the cancellation of trade marks held by famed Melbourne pub The Corner Hotel, which sued the fast food giant last year for allegedly violating its “Corner” trade marks with a experimental hipster cafe in Sydney.
European solar panel maker REC has struck back at a patent lawsuit filed by solar giant Hanwha QCELLS, saying it will petition the court to invalidate Hanwha’s patent for its passivation technology.
A Federal Court judge has questioned whether appeals from IP Australia should be allowed to proceed as hearings anew and not confined to the issues already run before the agency, in a ruling spanning 1,784 paragraphs that dismisses a challenge by chemical manufacturer SNF to a delegate’s decisions granting two mining patents to rival BASF.
The battle to acquire IP services company Xenith IP Group is set to intensify after the Australian Competition and Consumer Commission blessed a hostile offer by IPH Limited.
Kmart has been ordered to produce more documents related to changes made to the designs for its men’s cargo pants and shorts in a lawsuit alleging it violated the copyright for workwear company Globe International’s clothing designs.
IP Australia has challenged a patent application for a rearward-facing car seat, despite shooting down all the grounds of opposition raised by child safety product maker Dorel.
Aspiring MP Clive Palmer has filed his defence against a lawsuit by US record label Universal Music over his take on the 1980s rock anthem ‘We’re Not Gonna Take It’, saying he didn’t infringe any copyright on the song because it’s not original.
Pharmaceutical giant Mylan has been ordered to hand over documents relating to its proposed launch of a generic version of its cholesterol drug Lipidil to rival Sun Pharma in advance of a hearing on Mylan’s request for an order blocking Sun from launching its own generic version of the drug.